Navigation Links
Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets
Date:11/8/2010

ST LOUIS, Nov. 8, 2010 /PRNewswire-FirstCall/ -- Solutia Inc. (NYSE: SOA) announced today that it has sold its Perkalink® business and entered into a definitive agreement to sell select Primary Accelerators assets to LANXESS, a Germany-based specialty chemicals company.      

(Logo: http://photos.prnewswire.com/prnh/20081029/AQW096LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081029/AQW096LOGO)

"The sale of the Perkalink business is yet another strategic step forward in focusing Solutia's Flexsys® portfolio on the manufacture and supply of high-value, global market-leading rubber chemicals," said Greta Senn, president and general manager of Solutia's Technical Specialties division.  "In addition, our ability to sell select assets of Solutia's discontinued Primary Accelerators business allows us to maximize the value of those assets as we exit the business."

Solutia's Technical Specialties division offers advanced chemical and specialty products that meet or exceed rigorous specifications and are distributed through a reliable, global supply system. As one of the world's largest producers of chemicals for the rubber and tire industry, Flexsys products help control the process of manufacturing rubber, while improving its durability, flexibility and appearance.  The Perkalink business represented less than 1% of Solutia's consolidated sales in 2009.  For more information on Solutia and its diverse portfolio of product solutions, please visit www.solutia.com .

Notes to Editor:  Solutia, Flexsys and the Infinity Logo® and all other trademarks listed below are trademarks of Solutia Inc. and/or its affiliates.

Forward Looking Statements

This press release may contain forward-looking statements, which can be identified by the use of words such as "believes," "expects," "may," "will," "intends," "plans," "estimates" or "anticipates," or other comparable terminology, or by discussions of strategy, plans or intentions.  These statements are based on management's current expectations and assumptions about the industries in which Solutia operates.  Forward-looking statements are not guarantees of future performance and are subject to significant risks and uncertainties that may cause actual results or achievements to be materially different from the future results or achievements expressed or implied by the forward-looking statements.  These risks and uncertainties include, but are not limited to, those risk and uncertainties described in Solutia's most recent Annual Report on Form 10-K, including under "Cautionary Statement About Forward Looking Statements" and "Risk Factors", and Solutia's quarterly reports on Form 10-Q.  These reports can be accessed through the "Investors" section of Solutia's website at www.solutia.com.  Solutia disclaims any intent or obligation to update or revise any forward-looking statements in response to new information, unforeseen events, changed circumstances or any other occurrence.

Corporate Profile

Solutia is a market-leading performance materials and specialty chemicals company. The company focuses on providing solutions for a better life through a range of products, including: Saflex® polyvinyl butyral interlayers for glass lamination and for photovoltaic module encapsulation and VISTASOLAR® ethylene vinyl acetate films for photovoltaic module encapsulation;  LLumar®, Vista™, EnerLogic™, FormulaOne®, Gila®, V-KOOL®, Huper Optik®, IQue™, Sun-X® and Nanolux® aftermarket performance films for automotive and architectural applications; Flexvue™ advanced film component solutions for solar and electronic technologies; and technical specialties products including Crystex® insoluble sulfur, Santoflex® PPD antidegradants, Therminol® heat transfer fluids and Skydrol® aviation hydraulic fluids. Solutia's businesses are world leaders in each of their market segments. With its headquarters in St. Louis, Missouri, USA, the company operates globally with approximately 3,400 employees in more than 50 worldwide locations. More information is available at www.Solutia.com .


'/>"/>
SOURCE Solutia Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Solutia Opens New Photovoltaic Laboratory
2. Solutia to Present at Credit Suisse Future Energy Conference
3. Solutia Reports Third Quarter 2009 Results
4. Solutia Reports First Quarter 2009 Results
5. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
6. TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Hoya Announces Second Quarter Financial Results
9. Metamark Genetics, Inc. Announces New Chief Executive Officer
10. Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
11. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
Breaking Biology Technology:
(Date:8/23/2017)... ARMONK, N.Y. , Aug. 23, 2017  The general public,s help ... the human microbiome—the bacteria that live in and on the human body ... ... bacteria in the human microbiome, starting with the gut. The project's goal ... in disease. Photo credit: IBM ...
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):